Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment

作者：Voss Karsten; Falke Karen; Bernsdorf Arne; Grabow Niels; Kastner Christian; Sternberg Katrin; Minrath Ingo; Eickner Thomas; Wree Andreas; Schmitz Klaus Peter; Guthoff Rudolf; Witt Martin; Hovakimyan Marina^*

来源：Journal of Controlled Release, 2015, 214: 1-11.

DOI：10.1016/j.jconrel.2015.06.035

In this study we present the development of an injectable polymeric drug delivery system for subconjunctival treatment of primary open angle glaucoma. The system consists of hyaluronic acid sodium salt (HA), which is commonly used in ophthalmology in anterior segment surgery, and an isocyanate-functionalized 1,2-ethylene glycol bis(dilactic acid) (ELA-NCO). The polymer mixtures with different ratios of HA to ELA-NCO (1/1, 1/4, and 1/10 (v/v)) were investigated for biocompatibility, degradation behavior and applicability as a sustained release system. For the latter, the lipophilic latanoprost ester pro-drug (LA) was incorporated into the HA/ELA-NCO system.
In vitro, a sustained LA release over a period of about 60 days was achieved. In cell culture experiments, the HA/ELA-NCO (1/1, (v/v)) system was proven to be biocompatible for human and rabbit Tenon's fibroblasts. Examination of in vitro degradation behavior revealed a total mass loss of more than 60% during the observation period of 26 weeks.
In vivo, LA was continuously released for 152 days into rabbit aqueous humor and serum. Histological investigations revealed a marked leuko-lymphocytic infiltration soon after subconjunctival injection. Thereafter, the initial tissue reaction declined concomitantly with a continuous degradation of the polymer, which was completed after 10 months.
Our study demonstrates the suitability of the polymer resulting from the reaction of HA with ELA-NCO as an injectable local drug delivery system for glaucoma therapy, combining biocompatibility and biodegradability with prolonged drug release.

• 出版日期2015-9-28